{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-013387","form_type":"8-K","ticker":"PTCT","cik":"0001070081","company_name":"PTC THERAPEUTICS, INC.","filed_at":"2024-10-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.573946+00:00","generated_at":"2026-05-30T12:42:23.147243+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"CHMP maintains negative opinion on PTC's Translarna renewal; EC decision awaited in ~67 days","bullets":["CHMP upheld negative opinion on renewal of conditional marketing authorization for Translarna (ataluren) in nmDMD after re-examination.","European Commission expected to decide on opinion adoption in approximately 67 days; Translarna remains authorized pending EC review.","CEO cites totality of evidence from three placebo-controlled trials and STRIDE registry as supportive of continued authorization.","CHMP based decision on primary analysis subpopulation of Study 041; PTC will provide all possible evidence to EC for continued authorization.","Translarna currently authorized in Europe; PTC continues to ensure availability for nmDMD patients during review."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-013387","json":"https://secwatch.observer/filing/0001558370-24-013387.json","markdown":"https://secwatch.observer/filing/0001558370-24-013387.md","text":"https://secwatch.observer/filing/0001558370-24-013387.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070081/000155837024013387/0001558370-24-013387-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070081/000155837024013387/tmb-20241018x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T12:42:23.147243+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}